title: [Effect of Post-Gastrectomy Adjuvant S-1 Chemotherapy on Muscle Volume in Gastric Cancer Patients].
abstract: OBJECTIVE
  To examine the effect of S-1 adjuvant chemotherapy on muscle volume after curative gastrectomy in gastric cancer patients.
  
  
  METHODS
  Forty-eight gastric cancer patients (31 men and 17 women) who underwent curative gastrectomy (distal gastrectomy: n=37, and total gastrectomy: n=11) between April 2010 and July 2011 were enrolled in this study. Sixteen patients underwent S-1 adjuvant chemotherapy (S-1 group) for 1 year after the operation, and 32 patients did not (NT group).
  
  
  METHODS
  The psoas muscle areas were measured at the fourth lumbar vertebrae on CT images obtained before the operation, and at 6, 12, and 24 months after the operation. Muscle areas was statistically examined by comparing the preoperative and postoperative ratios.
  
  
  RESULTS
  The muscle areas 12 months after the operation decreased to 0.86 ± 0.11 in the S-1 group and to 0.96 ± 0.08 in the NT group (p<0.05), and the significant difference disappeared at 24 months (0.93 ± 0.10 vs. 0.93 ± 0.11, NS). In the patients who underwent distal gastrectomy, the muscle areas decreased to 0.90 ± 0.05 in the S-1 group and to 0.96 ± 0.09 in the NT group at 12 months (p<0.05). Meanwhile, in those who underwent total gastrectomy, the muscle areas decreased to 0.80 ± 0.15 and 0.93 ± 0.03, respectively (NS).
  
  
  CONCLUSIONS
  S-1 adjuvant chemotherapy affected muscle volume loss after gastrectomy in the gastric cancer patients, but the patients recovered from the adverse effect by 12 months after chemotherapy.
authors: Dept. of Surgery, Toyonaka Municipal Hospital.
authors: Takashi
authors: T
authors: Iwazawa
authors: Kenshu
authors: K
authors: Kawanishi
authors: Junya
authors: J
authors: Fujita
authors: Akihiro
authors: A
authors: Takata
authors: Masashi
authors: M
authors: Hirota
authors: Hiroshi
authors: H
authors: Imamura
authors: Atsuyo
authors: A
authors: Ikeda
authors: Kentarou
authors: K
authors: Hokonohara
authors: Chizu
authors: C
authors: Yoneyama
authors: Akira
authors: A
authors: Kameyama
authors: Go
authors: G
authors: Shinke
authors: Kazuteru
authors: K
authors: Oshima
authors: Tsukasa
authors: T
authors: Tanida
authors: Hisanori
authors: H
authors: Hatano
authors: Takehiro
authors: T
authors: Noda
authors: Takamichi
authors: T
authors: Komori
authors: Shunji
authors: S
authors: Morita
authors: Kenzou
authors: K
authors: Akagi
authors: Keizou
authors: K
authors: Dono
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D004338:Drug Combinations; D005260:Female; D005743:Gastrectomy / Q000009:adverse effects; D006801:Humans; D008297:Male; D018482:Muscle, Skeletal / Q000166:cytology / Q000187:drug effects*; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid